Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Rana Al-Hallaq
AddedMar 31, 2024
UpdatedMay 31, 2026
Rana Al-Hallaq

Rana Al-Hallaq

Board Member, Blade Therapeutics

CrunchbaseLinkedIn

Rana Al-Hallaq's Career

Blade Therapeutics
Blade Therapeutics

South San Francisco, CA, US

Board Member· Board
ReCode Therapeutics
ReCode Therapeutics

Menlo Park, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Rana Al-Hallaq's Career

Blade Therapeutics
Blade Therapeutics
Series D$51.5M282013South San Francisco, CA, US
Board Member· Board

Leadership at Blade Therapeutics

Wendye RobbinsWendye RobbinsCEO
Mark TimneyMark TimneyBoard Member
Jim ScopaJim ScopaBoard Member
Luke EvninLuke EvninBoard Member
Peter Van VlasselaerPeter Van VlasselaerBoard Member
Harry DietzHarry DietzFounder

Similar to Blade Therapeutics

Pliant TherapeuticsPliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
Mistral TherapeuticsMistral TherapeuticsSan Diego, CA, USFibrosis Treatmentsest. 2011Mistral TherapeuticsSan Diego, CA, US · est. 2011

Mistral Therapeutics: A San Diego-based biotech firm specializing in innovative fibrosis treatments.

Series B · $36.4M6
ReCode Therapeutics
ReCode Therapeutics
Series B$521.8M1432015Menlo Park, CA, US
Board Member· Board

Leadership at ReCode Therapeutics

Ed HurwitzEd HurwitzBoard Member
Michael Torres, PhDMichael Torres, PhDCo-Founder
Daniel SiegwartDaniel SiegwartCo-Founder
Shehnaaz SulimanShehnaaz SulimanBoard Member
Alan ColowickAlan ColowickBoard Member

Similar to ReCode Therapeutics

Artan BioArtan BioSt. Petersburg, FL, USArtan BioSt. Petersburg, FL, US

Artan Bio develops engineered transfer RNA therapies that target mutation-driven aging biology.

Seed · $1M
Code BiotherapeuticsCode BiotherapeuticsHatfield, PA, USGene Therapyest. 2020Code BiotherapeuticsHatfield, PA, US · est. 2020

Code Biotherapeutics: Pioneering non-viral gene therapies for serious genetic diseases.

Series A · $85M47
Encoded TherapeuticsEncoded TherapeuticsSouth San Francisco, CA, USPrecision Therapiesest. 2014Encoded TherapeuticsSouth San Francisco, CA, US · est. 2014

Encoded: Leveraging human genome power for effective precision therapies in genetic disorders.

Series D · $239.1M200

Rana Al-Hallaq's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Rana Al-Hallaq

Andy TranAndy TranBoard Member · Maze TherapeuticsPerry HackettPerry HackettBoard Member · NovoCladeDave StackDave StackBoard Member · Elixir PharmaceuticalsRanjeet AlexisRanjeet AlexisBoard Member · WiTricityBlake BorgesonBlake BorgesonBoard Member · Recursion Pharmaceuticals